In a trial of more than 7000 patients with T2DM, the SGLT2 inhibitor empagliflozin significantly reduced ALT and AST, though liver fat and fibrosis were not measured outcomes [41]. Here, SLC5A2 is linked to type 2 diabetes mellitus.